Kidney Transplantation Clinical Trial
— QUANTIFOTOfficial title:
Use of QuantiFERON® CMV in the Therapeutic Decision in Asymptomatic CMV Infection in Solid Organ Transplant Recipients
Context Cytomegalovirus (CMV) infection is a frequent and potentially severe event in solid organ transplant (SOT) recipients. Most of available treatment display adverse effects that limit their use. Therefore, in case of an infection, it is of primary importance to identify the patients at high risk of severe infection and/or disease, and who ill benefit the most from antiviral therapy. As CMV infection is mainly controlled by cellular immunity, measuring specific anti-CMV T lymphocyte immunity could be an interesting tool for identifying these at-risk individuals. One of these tests is the QuantiFERON-CMV (QF-CMV) assay (QuiagenTM, Courtabœuf, France). Aim of the study The aim of the study is to determine the extent to which the QF-CMV can be use to identify, among SOT recipients with a CMV viremia, those that may not need antiviral therapy. Methods Participation to the study will be proposed to SOT recipients with an asymptomatic CMV infection with a blood viral load between 1,000 and 15,000 IU/mL. The QF-CMV will be performed in included participants, and the result will be given or not to the clinician in charge (according to the attributed group through randomisation). - In the group without result communication, the clinician in charge will determine whether a treatment is needed according to the guidelines and the local practices. - in the group with result communication, the clinician in charge will be advised not to introduce antiviral therapy if the result is positive, and to determine whether a treatment is needed according to the guidelines and the local practices if the result is positive. In the following weeks, the viral load will be monitored, along with creatininemia, cell blood count, and kalemia (to detect antiviral adverse effect). The participants will be sampled: - 5 to 12 days after QF-CMV sampling (V2) ; - 7 to 14 days days after V2 (V3 - between D12 and D26) ; - 7 to 14 days days after V3 (V4 - between D19 and D40) . Endpoints The primary endpoint is the rate of uncontrolled infection 5 to 12 days after QF-CMV sampling, defined as follows: - Blood CMV viral load >10,000 IU/mL [4 log]; - And/or increase in blood viral load ≥0.5 log IU/mL with CV otherwise >5000 IU/mL; - And/or the onset of CMV disease. The secondary endpoint is the is the occurrence antiviral adverse effects (hematoxicity or nephrotoxicity).
Status | Not yet recruiting |
Enrollment | 288 |
Est. completion date | June 15, 2026 |
Est. primary completion date | June 15, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years. - Solid organ transplant recipient (heart, kidney, liver and lung) - Detectable CMV viral load between 1,000 and 15,000 IU/mL (including 2 borderline values): - Asymptomatic (no fever or organ dysfunction) ; - Occurrence within 2 years of transplantation in the absence of primary post-transplant anti-CMV prophylaxis; - Or within 2 years of discontinuation of primary post-transplant anti-CMV prophylaxis if such prophylaxis was used. - Having signed an informed consent form. - Affiliated to a social security scheme. Exclusion Criteria: - Presence of anti-Herpesviridae treatment when CMV replication is detected ([val]aciclovir, [val]ganciclovir, foscarnet, cidofovir, letermovir, maribavir, anti-CMV immunoglobulins, cidofovir, brincidofovir). - Pregnant or breast-feeding women. - Persons under guardianship or trusteeship. - Subjects under administrative or judicial supervision. - Subject unable to be contacted in case of emergency. |
Country | Name | City | State |
---|---|---|---|
France | Olivier EPAULARD | Grenoble | Isere |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Grenoble |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | proportion of participants with CMV viral load (>10,000 IU/mL, or increase =0.5 log IU/mL) | Uncontrolled infection 5 to 12 days after QF-CMV sampling is defined as follows:
Blood CMV viral load >10,000 IU/mL [4 log]; And/or increase in blood viral load =0.5 log IU/mL with CV otherwise >5000 IU/mL |
5 to 12 days after QF-CMV sampling, and up to 40 days after first CMV detection | |
Primary | proportion of participants with CMV disease | CMV disease is defined as follows:
pneumonia onset colitis onset encephalitis onset hepatitis onset |
5 to 12 days after QF-CMV sampling, and up to 40 days after first CMV detection | |
Secondary | proportion of participants with antiviral-associated anemia | hemoglobin <110 g/L or decrease >10% | 5 to 12 days after QF-CMV sampling, and up to 40 days after first CMV detection | |
Secondary | proportion of participants with antiviral-associated leucopenia | PNN <1000/mm3 or decrease >30% | 5 to 12 days after QF-CMV sampling, and up to 40 days after first CMV detection | |
Secondary | proportion of participants with antiviral-associated thrombopenia | platelets <130 G/L or decrease >20% | 5 to 12 days after QF-CMV sampling, and up to 40 days after first CMV detection | |
Secondary | proportion of participants with antiviral-associated tubulotoxicity (hypokaliemia) | kaliemia <3,5 mMol | 5 to 12 days after QF-CMV sampling, and up to 40 days after first CMV detection | |
Secondary | antiviral-associated kidney failure (creatininemia) | creatininemia increase >20% | 5 to 12 days after QF-CMV sampling, and up to 40 days after first CMV detection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT02723591 -
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT05945511 -
Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
|
||
Completed |
NCT02234349 -
Bile Acids and Incretins in Pancreas Kidney Transplant Patients
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT05934383 -
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
|
N/A | |
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Not yet recruiting |
NCT04540640 -
Oxygenated Machine Preservation in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Completed |
NCT02560558 -
Bela 8 Week Dosing
|
Phase 4 | |
Terminated |
NCT02417870 -
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02154815 -
Pre-emptive Kidney Transplantation Quality of Life
|
N/A | |
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Enrolling by invitation |
NCT01905514 -
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
|
N/A | |
Completed |
NCT02147210 -
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
|
N/A | |
Recruiting |
NCT01699360 -
The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 |